Cell-free Synthesis of the Hirudin Variant 1 of the Blood-sucking Leech Hirudo Medicinalis
Authors
Affiliations
Synthesis and purification of peptide drugs for medical applications is a challenging task. The leech-derived factor hirudin is in clinical use as an alternative to heparin in anticoagulatory therapies. So far, recombinant hirudin is mainly produced in bacterial or yeast expression systems. We describe the successful development and application of an alternative protocol for the synthesis of active hirudin based on a cell-free protein synthesis approach. Three different cell lysates were compared, and the effects of two different signal peptide sequences on the synthesis of mature hirudin were determined. The combination of K562 cell lysates and the endogenous wild-type signal peptide sequence was most effective. Cell-free synthesized hirudin showed a considerably higher anti-thrombin activity compared to recombinant hirudin produced in bacterial cells.
Casteleijn M, Abendroth U, Zemella A, Walter R, Rashmi R, Haag R Chem Rev. 2025; 125(3):1303-1331.
PMID: 39841856 PMC: 11826901. DOI: 10.1021/acs.chemrev.4c00126.
Endogenous fibrinolysis inhibitors in acute coronary syndrome.
Chandrasekar B Am Heart J Plus. 2024; 10:100058.
PMID: 38550400 PMC: 10978119. DOI: 10.1016/j.ahjo.2021.100058.
Hirudin in the Treatment of Chronic Kidney Disease.
Liu S, Cao Y, Zhang C Molecules. 2024; 29(5).
PMID: 38474541 PMC: 10935440. DOI: 10.3390/molecules29051029.
Cell-Free Display Techniques for Protein Evolution.
Li J, Yang Y, Li J, Li P, Qi H Adv Biochem Eng Biotechnol. 2023; 185:59-90.
PMID: 37306697 DOI: 10.1007/10_2023_227.
Shi P, Wei J, You H, Chen S, Tan F, Lu Z Sci Rep. 2023; 13(1):4943.
PMID: 36973525 PMC: 10042815. DOI: 10.1038/s41598-023-32303-2.